Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide

International Journal of Antimicrobial Agents

Volumn 23, Issue 2, 2004, Pages 197-199

  Jones, Ronald N ^a,b   Streit, Jennifer M ^a   Fritsche, Thomas R ^a  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Broth microdilution products; Dalbavancin; MIC comparison

Indexed keywords

DALBAVANCIN; GLYCOPEPTIDE; OXACILLIN; PENICILLIN G;

ACCURACY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DILUTION; ENTEROCOCCUS FAECALIS; GRAM NEGATIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; SHELF LIFE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS MITIS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PYOGENES; VALIDATION PROCESS;

EID: 0842285457     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.07.008     Document Type: Article

References (14)

1. Seltzer E., Goldstein B., Dorr M.-B., Davell J., Perry M., Henkel T. Dalbavancin: phase II demonstration of efficacy of a novel, weekly dosing regimen in skin and soft tissue infection (Abstract O143). Clin. Microbiol. Infect. Dis. 9:2003;22.
2. Candiani G., Abbondi M., Borgonovi M., Romano G., Parenti F. In vitro and in vivo antibacterial activity of BI397, a new semi-synthetic glycopeptide antibiotic. J. Antimicrob. Chemother. 43:1999;179-192.
3. Goldstein B.P., Candiani G.P., Arain T.M., Romano G., Ciciliato I., Becti M. Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic. Antimicrob. Agents Chemother. 39:1995;1580-1588.
4. Jones R.N., Biedenbach D.J., Johnson D.M., Pfaller M.A. In vitro evaluation of BI397, a novel glycopeptide antimicrobial agent. J. Chemother. 13:2001;244-254.
5. Malabarba A, Ciabatti R, Romano G, Ripamonti F, Candlani G, Abbondi M. F. BI397: a new developmental semisynthetic glycopeptide antibiotic (Abstract F-107). In: Proceedings of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego (CA); 1998.
6. Baquero F. Gram-positive resistance: challenge for the development of new antibiotics. J. Antimicrob. Chemother. 39:1997;1-6.
7. Jones R.N., Hare R.S., Sabatelli F.J. The Ziracin Susceptibility Testing Group. In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial. J. Antimicrob. Chemother. 31:1998;437-451.
8. Jones RN, Anderegg TR, Biedenbach DJ. Validation of commercial dry-form broth microdilution panels for susceptibility testing of AZD2563, a new long-acting oxazolidinone. Clin Microbiol Infect 2003;9:543-6.
9. Diekema D.J., Jones R.N. Oxazolidinones: a review. Drugs. 59:2000;7-16.
10. Jones R.N., Ballow C.H., Biedenbach D.J., Deinhart J.A., Schentag J.J. Antimicrobial activity of quinupristin/dalfopristin (RP 59500, Synercid®) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn. Microbiol. Infect. Dis. 31:1998;437-451.
11. Anderegg T.R., Biedenbach D.J., Jones R.N. Initial quality control evaluations for susceptibility testing of dalbavancin (BI397), an investigational glycopeptide with potent Gram-positive activity. J. Clin. Microbiol. 41:2003;2795-2796.
12. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-A6. Wayne (PA); 2003.
13. National Committee for Clinical Laboratory Standards. Development of in vitro susceptibility testing criteria and quality control parameters. 2nd ed. Approved Guideline M23-A2. Wayne (PA); 2001.
14. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. M100-S13. Supplemental Tables. Wayne (PA); 2003.